Group A | |||
Initial treatment(duration of 6 weeks) | |||
VDS | 3 mg/m 2 | IV | D1 D8 D15 D22 D29 D36 |
PSL | 2 mg/kg | oral | D1-D28, D29-42 weekly tapering |
Maintenance treatment(duration of 12 months) | |||
VDS | 3 mg/m 2 | IV | once per 3 weeks |
PSL | 2 mg/kg | oral | 5 days per 3 weeks |
Group B | |||
Initial treatment(duration of 6 weeks) | |||
VDS | 3 mg/m 2 | IV | D1 D8 D15 D22 D29 D36 |
PSL | 2 mg/kg | oral | D1-D28, D29-42 weekly tapering |
THP | 20 mg/m 2 | IV | D1 D15 D29 |
CTX | 10 mg/kg | IV | D1-5 D15-19 D29-33 |
MTXa | 25 mg/m 2 | oral | once per week |
Vemur# | 15-20 mg/kg | oral | twice per day |
Maintenance treatment(duration of 12 months) | |||
VDS | 3 mg/m 2 | IV | once per 3 weeks |
PSL | 2 mg/kg | oral | 5 days per 3 weeks |
THP | 20 mg/m 2 | IV | once per 6 weeks (W1, W7, W13,W19) |
CTX | 10 mg/kg | IV | once per 6 weeks (W4, W10, W16,W22) |
6MP | 50 mg/m 2 | oral | once per day |
MTXa | 25 mg/m 2 | oral | once per week |
Vemur# | 15-20 mg/kg | oral | twice per day |